We next evaluated the relationship between MYC/BCL2/BCL6 subpopulations and prognosis, using pretreatment biopsies of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)–treated DLBCL patients, with clinical data available from three cohorts—National University Hospital, Singapore (NUH, n = 98), SGH (n = 41), and MDA (n = 36). The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.